Halberd (Halberd) EV-to-FCF : (As of May. 22, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Halberd EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Halberd's Enterprise Value is $0.37 Mil. Halberd does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Jul. 2023. Therefore, GuruFocus does not calculate Halberd's EV-to-FCF at this moment.

The historical rank and industry rank for Halberd's EV-to-FCF or its related term are showing as below:

HALB' s EV-to-FCF Range Over the Past 10 Years
Min: -1.7 Med: 0 Max: 0
Current: -1.45

HALB's EV-to-FCF is ranked worse than
100% of 376 companies
in the Biotechnology industry
Industry Median: 9.49 vs HALB: -1.45

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Halberd's stock price is $0.00835. Halberd does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2023. Therefore, GuruFocus does not calculate Halberd's PE Ratio at this moment.

Halberd EV-to-FCF Historical Data

The historical data trend for Halberd's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd EV-to-FCF Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

EV-to-FCF

-7.08

-22.22

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
EV-to-FCF	-	-7.08	-22.22

Competitive Comparison of Halberd's EV-to-FCF

For the Biotechnology subindustry, Halberd's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Halberd's EV-to-FCF falls into.

Halberd EV-to-FCF Calculation

Halberd's EV-to-FCF for today is calculated as:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	0.365	/
	=

Halberd (OTCPK:HALB) EV-to-FCF Explanation

Halberd's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.00835	/
	=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Halberd EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Halberd's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » EV-to-FCF

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236